Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.

American heart journal

Volumn 148, Issue 5, 2004, Pages 889-894

  Tang, W H Wilson ^a   Vagelos, Randall H ^a   Yee, Yin Gail ^a   Fowler, Michael B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALDOSTERONE; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; RENIN;

ARTICLE; BLOOD; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; GENOTYPE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RENIN;

MLCS; MLOWN;

EID: 16644388739     PISSN: None     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.05.020     Document Type: Article

References (0)